Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available
Protocol ID
iMATRIX (GO42286)
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
Relapse/refractory
Location
NSW
Sponsor
Hoffmann-La Roche
Trial Status
Open
Sites
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 17 Years
International registry ID's
NCT04774718
Back to Registry
Study Title A Phase I/II Open-Label Multicenter Study Evaluating the Safety Pharmacokinetics and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available
Protocol ID iMATRIX (GO42286)
Disease (Sub Disease) Solid tumours
Diagnosis Stage Relapse/refractory
Location NSW
Sponsor Hoffmann-La Roche
Links https://clinicaltrials.gov/ct2/show/NCT04774718
Trial Status Open
Trial Open Date 26/07/2021
Sites Sydney Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility up to 17 Years
International registry ID's NCT04774718